2 registrations that name cannabigerol as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT06115603
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
Phase 2
University of Arkansas, Fayetteville
About 76 people
Started Dec 14, 2024
In plain words A Phase 2 study of cannabigerol in people 18 to 55, run by University of Arkansas, Fayetteville. It plans to enroll about 76 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 55; healthy volunteers accepted. Conditions: Attention-Deficit/Hyperactivity Disorder.
Between 18 and 55-years-old.
BMI between 18 and 35 kg/m2.
Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A.
Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND.
32 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabigerol; Placebo
Registered summary
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07577999
The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy
Early phase 1
Stanford University
About 20 people
Starts Jul 2027 (estimated)
In plain words An early phase 1 study of cannabigerol in people 18 and older, run by Stanford University. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Non-metastatic Bladder Cancer.
18 years of age or older
Non-metastatic bladder cancer scheduled to undergo radical cystectomy and urinary diversion
Patient is able to understand consent and is willing and able to provide written informed consent
Patient makes their own medical decisions
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Cannabigerol
Registered summary
This will be an open-label, single group supportive care pilot study in which patients are given cannabinoid gummies in the perioperative setting to alleviate RC/UD symptoms and improve quality of life. The primary objective will be to evaluate the safety and tolerability of a cannabigerol supplement used perioperatively (from 14 days prior to surgery to 30 days following surgery) by patients undergoing radical cystectomy with urinary diversion (RC/UD).